4‐Ethoxycarbonyloxy‐3,5‐dimethoxybenzanilide (I), 3‐dimethylamino‐benzanilide (II), N(3,4‐dimethoxyphenethyl)‐4‐ethoxycarbonyloxy‐ 3,5‐dimethoxybenzamide (III), N‐(3,4‐dimethoxyphenethyl)‐3‐dimethylaminobenzamide (IV), 4‐(3,4,5‐trimethoxybenzoyloxy)‐ benzanilide (V), 4‐(4‐ethoxycarbonyloxy‐3,5‐dimethoxybenzoyloxy)‐ benzanilide (VI), 3‐acetoxy‐N‐(3,4‐dimethoxyphenethyl)cyclohexane‐ carboxyamide (VII), 3‐anisoyloxy‐N‐(3,4‐dimethoxyphenethyl)cyclo‐ hexanecarboxyamide (VIII), N‐(3,4‐dimethoxyphenethyl)‐3‐veratroyl‐ oxycyclohexanecarboxyamide (IX), N‐(3,4‐dimethoxyphenethyl)‐3‐ trimethoxybenzoyloxycyclohexanecarboxyamide (X), and N‐(3,4‐dimethoxyphenethyl)‐4‐trimethoxy benzoyloxycyclohexanecarboxyamide (XI) have been prepared. Eight of the compounds, I‐VII and X, were compared with reserpine for their ability to potentiate barbiturate hypnosis in mice and to deplete the 5‐hydroxytryptamine content of rat brain. None of them lowered the brain 5‐hydroxytryptamine content but several showed barbiturate potentiation. Compound V was the most potent of the series in producing potentiation of barbiturate hypnosis, being about one tenth as action as reserpine.